TG Therapeutics Reports 70.3% Revenue Growth to $240.3 Million in Latest Quarter

TG Therapeutics, Inc. reported significant financial performance in its latest quarterly filing, with total revenue reaching $240.3 million for the three months ended June 30, 2026, a 70.3% increase from $141.1 million in the same period last year. The growth was primarily driven by product revenue, which amounted to $235.8 million, up from $138.8 million, reflecting increased market penetration of its flagship product, BRIUMVI (ublituximab), in the U.S. and sales to its ex-U.S. licensing partner, Neuraxpharm. For the first half of 2026, total revenue was $445.3 million, compared to $262.0 million for the same period in 2025.

Despite the revenue growth, TG Therapeutics reported a net income of $7.8 million for the second quarter, down from $28.2 million in the prior year, largely due to increased costs associated with research and development (R&D) and selling, general, and administrative (SG&A) expenses. R&D expenses surged to $95.3 million from $31.8 million, driven by higher manufacturing costs related to the development of a subcutaneous formulation of BRIUMVI. SG&A expenses also rose to $82.1 million from $55.6 million, reflecting increased marketing efforts and personnel costs associated with the commercialization of BRIUMVI.

In terms of operational developments, TG Therapeutics has made strides in expanding its product offerings and market presence. The company announced positive topline results from the Phase 3 ENHANCE trial, which evaluated a simplified dosing regimen for BRIUMVI, and initiated a Phase 2 clinical trial for BRIUMVI in treatment-resistant schizophrenia. Additionally, the company is advancing its subcutaneous formulation of ublituximab, with topline data from a Phase 3 trial expected by early 2027. As of June 30, 2026, the company had an accumulated deficit of approximately $1.1 billion and $612.3 million in cash and cash equivalents, indicating a strong liquidity position to support ongoing operations.

The company’s strategic focus includes not only the commercialization of BRIUMVI but also the exploration of complementary products and technologies through potential in-licensing and acquisition opportunities. TG Therapeutics anticipates that its existing cash and projected revenues will be sufficient to fund operations for at least the next twelve months. However, the company acknowledges that it may seek additional financing to support strategic initiatives as needed.

Overall, TG Therapeutics is positioned for continued growth, driven by its expanding product portfolio and ongoing clinical trials, although it faces challenges related to rising operational costs and market competition. The company remains committed to maintaining profitability while investing in its research and development efforts to enhance its therapeutic offerings.